TITLE

Eribulin Mesylate Injection (Halaven)

AUTHOR(S)
Elliott, William T.; Chan, James
PUB. DATE
January 2011
SOURCE
Internal Medicine Alert;1/29/2011, Vol. 33 Issue 2, p14
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article examines the efficacy of eribulin mesylate, a halichondrins marketed by Eisai Inc. as Halaven, as chemotherapeutic agent for the treatment of metastatic breast cancer.
ACCESSION #
58516387

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics